ArticleVeterinary research2026
Intracellularly delivered nanobody targeting the nucleocapsid protein effectively inhibits porcine deltacoronavirus replication.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Camelid VHHs as a Versatile Platform for Combating Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Porcine deltacoronavirus (PDCoV) is an emerging enteropathogenic coronavirus that causes acute diarrhea in piglets and poses a potential zoonotic risk. Effective antiviral agents against PDCoV are currently lacking. In this study, we identified a nanobody, designated 62Nb, that specifically targets the nucleocapsid (N) protein of PDCoV and potently inhibits viral replication. Stable expression of 62Nb in porcine ST cells significantly reduced N protein levels, viral RNA copies, and progeny virus titers without affecting cell viability, indicating a robust antiviral effect. Mechanistic analysis revealed that 62Nb interferes with post-entry intracellular stages of the viral life cycle rather than viral attachment or entry. To enable extracellular delivery, we further engineered a TAT-fused nanobody (62Nb-TAT) that efficiently penetrated IPEC-J2 cells and maintained strong binding affinity to the N protein. The intracellularly delivered 62Nb-TAT markedly suppressed PDCoV replication in a dose-dependent manner, with an EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.